Molecular Partners AGMolecular Partners AGMolecular Partners AG

Molecular Partners AG

No trades
See on Supercharts

MOLN fundamentals

Key facts

Market capitalization
Founded
CEO
Website
About

Molecular Partners AG engages in the development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. It also develops its products through its brand known as DARPins, which targets specific and potent monoclonal antibodies that offers potential to address existing limitations of antibody drugs. The company products include Abicipar, MP0250/MP0274 and Clinical Trials. The company was founded by Christian Zahnd, Patrick Amstutz, Patrik Forrer, Andreas Plückthun, and Michael Tobias Stumpp on November 22, 2004 and is headquartered in Schlieren, Switzerland.

Valuation

Fundamental metrics to determine fair value of the stock

Summary
No data available
There's currently no market capitalization, revenue or net income data to show.
Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

MOLN does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company